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Purpose: The purpose of this study was to determine if downregulation of LIM kinase 1 (LIMK1) by genetic deletion or
direct application of LIMK1-targeted siRNA could suppress TGF-β mediated ocular inflammation and fibrosis.
Methods: LIMK1 specific siRNAs designed from the human sequence were transfected into human corneal fibroblasts
in culture. Immunofluorescence and immunoblotting were performed to examine the fibronectin assembly. The effects of
LIMK1 downregulation on actin cytoskeleton organization and focal adhesion formation were studied. A wound closure
assay was used to assess cell migration in in vitro fibroblast cultures. The in vivo effects of LIMK1 genetic deletion or
downregulation by mouse siRNA were evaluated in a mouse model of ocular inflammation generated by subconjunctival
injection of phosphate buffered saline and latex beads. Cellularity on tissue sections was examined after staining with
hematoxylin and eosin. Anti-CD45 antibody was used for the leukocyte detection.
Results:  Downregulation  of  LIMK1  in  cultured  corneal  fibroblasts  impaired  fibronectin  secretion  and  assembly,
diminished actin polymerization and focal adhesion formation, and retarded cell migration. In the mouse model of ocular
inflammation,  both  genetic  deletion  and  downregulation  of  LIMK1  by  siRNA  significantly  reduced  inflammatory
response.
Conclusions: Downregulation of LIMK1 was efficacious to decrease the ocular inflammation. We disclose a possibility
that LIMK1 may mediate TGF-β-dependent signaling during ocular inflammation. A direct application of siRNA into eyes
to downregulate LIMK1 expression may provide a novel therapy for suppression and prevention of ocular inflammation
and fibrosis.
LIM kinase 1 (LIMK1) is a serine/threonine kinase that
regulates microtubule stability and actin polymerization [1].
LIMK1 promotes actin polymerization by phosphorylation
and inactivation of the actin depolymerization factor – cofilin
[2,3]. It also negatively regulates microtubule dynamics and
assembly via phosphorylation of p25/TPPP [4]. LIMK1 is
activated  via  phosphorylation  by  downstream  effectors  of
small GTPases: Rho kinase (ROCK) [5]; p21 protein (Cdc42/
Rac)-activated kinase (PAK1) [6]; and PAK4 [7].
Transforming  growth  factor-β  (TGF-β),  a  family  of
cytokines, is known to be a key mediator of fibrotic responses
such as fibronectin deposition and cell migration to wounding
site  [8].  This  factor  has  been  implicated  in  a  variety  of
conditions  that  include  proliferative  vitreoretinopathy  [9],
cataract  formation  [10],  corneal  opacities  [11],  and
subconjunctival scarring, a complication of filtration surgery
in glaucoma [12,13].
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There have been reports of cross-talk between LIMK1
and  TGF-β  receptor  superfamilies.  A  direct  association
between LIMK1 and bone morphogenetic protein receptor
type  II  (BMPR-II),  a  member  of  the  TGF-β  superfamily,
mediated actin cytoskeleton dynamics [14,15]. It has also
been shown that TGF-β type I receptor can indirectly activate
LIMK2, a member of the LIMK family, through Rho and its
downstream effector ROCK1 [16] to regulate actin assembly.
In the glaucoma filtration surgery, postoperative fibrosis
or scarring at the wound site is a critical determinant of the
surgical outcome [17,18]. Although anti-scarring agents such
as mitomycin C and 5-fluorouracil can prevent post-operative
scarring and improve surgical outcome [19,20], they cause
widespread fibroblast cell death and are often associated with
severe  and  potentially  blinding  complications  [21,22].
Therefore targeting one of the pro-inflammatory pathways via
siRNA-dependent  protein  downregulation  might  be  an
effective strategy to reduce ocular inflammation and fibrosis.
We have recently determined that LIMK1 plays a pro-
inflammatory  role  in  mouse  lungs  via  disruption  of
endothelial  barrier  function  and  promotion  of  leukocyte
diapedesis  through  regulation  of  cytoskeleton  dynamics
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1951(unpublished  data).  The  important  role  of  LIMK1  during
inflammatory response and its possible cross-talk with TGF-
β have led us to hypothesize that LIMK1 may be involved in
inflammation  through  TGF-β  signaling,  and  that
downregulation of LIMK1 might be an effective strategy to
suppress ocular inflammation and fibrosis.
In the current study, the RNA interference and genetic
deletion approaches were employed to test our hypothesis. We
showed here that downregulation of LIMK1 in human corneal
fibroblasts  led  to  a  significant  decrease  in  fibronectin
deposition. The actin stress fibers and focal adhesions were
diminished  and  the  fibroblast  migration  was  retarded.
Moreover, downregulation of LIMK1 in a mouse model via
both  genetic  deletion  and  direct  application  of  LIMK1-
targeted  siRNA  in  the  eyes  markedly  reduced  ocular
inflammation.
METHODS
Cell cultures: Normal human corneas from donors aged 13,
29, 34, 45, and 47 years were obtained from the Illinois Eye
Bank (Chicago, IL). The procurement of tissues was approved
by the Institutional Review Board at the University of Illinois
at Chicago in compliance with the declaration of Helsinki. The
endothelium-Descemet’s membrane was stripped off under a
dissecting microscope. The stroma was then mechanically
separated from the epithelium-stroma and used as an explant
to  initiate  corneal  fibroblast  cultures.  The  cells  were
maintained  in  Dulbecco's  modified  Eagle's  minimum
essential medium (MEM) supplemented with glutamine, 10%
fetal calf serum, 5% calf serum, nonessential and essential
amino acids, and antibiotics as previously described [23]. All
of the in vitro experiments were repeated at least 3 times.
Results were confirmed with second- or third-passaged cells
derived independently from at least 3 different donors.
LIMK1 siRNA sequences: Double-stranded siRNA targeted
against human LIMK1: CCU GGA GGG AAG AAC GUA
UUU, and mismatch siRNA CCU GAA AGA AAA AAC
GUA UUU (where 4 nucleotides were mutated G/A) were
from Dharmacon (Chicago, IL). The siRNA was described
previously  [1].  The  specificity  of  the  LIMK1  siRNA  was
verified  or  the  siRNA  study  was  validated  by  using  1)
mismatch  controls,  where  mutation  of  only  several
nucleotides completely abolished the silencing effect; and 2)
several siRNAs targeted against different regions on LIMK1
mRNA, which showed similar silencing effects. The double-
stranded mouse counterpart of the LIMK1 siRNA: ACC GGA
UCU UGG AAA UCA AUU, and negative control siRNA
were from Qiagen (Valencia, CA).
Transfection  of  siRNA  duplexes:  Normal  human  corneal
fibroblasts  were  transfected  with  LIMK1  specific  siRNA
duplex  (50  or  100  nM  final  concentration)  or  scrambled
siRNA using TransIT-TKO reagent (Takara Mirus, Madison,
WI)  according  to  the  manufacturer’s  protocol.  Scrambled
siRNA was used as a negative control at 100 nM concentration
in all experiments. The cells were harvested 48 or 72 h after
transfection for analysis. Also as controls, corneal fibroblasts
were either untreated or treated only with TransIT-TKO.
Fibronectin, actin, and paxillin staining: Corneal fibroblasts
were plated at a confluent or sub-confluent density onto 8 well
glass chamber slides (Nalge Nunc International, Naperville,
IL) without extracellular matrix (ECM) coating. The cells
were transfected the next day and were fixed in cold methanol
without permeabilization to examine the fibronectin network
48 or 72 h after transfection. For actin and paxillin staining,
cells were fixed in paraformaldehyde-lysine-phosphate buffer
and  permeabilized  in  0.2%  Triton  X-100.  To  carry  out
immunostaining,  corneal  fibroblasts  were  incubated  with
polyclonal  rabbit  anti-human  fibronectin  (1:100;  BD
Biosciences,  Lexington,  KY)  or  monoclonal  anti-paxillin
(1:100;  Millipore,  Billercia,  MA).  FITC-goat  anti-rabbit
(1:200)  or  Cy3-goat  anti-mouse  (1:200;  Jackson
ImmunoResearch, West Grove, PA) IgG was used as the
secondary antibody. The actin structure was visualized after
incubation  for  40  min  with  Alexa  488-phalloidin  (1:40;
Molecular Probes, Eugene, OR). The nuclei of the cells were
counterstained  with  4’,6’-diamidino-2-phenylindole
dihydrochloride (DAPI). The slides were examined under a
Zeiss 100M microscope.
Western  blotting:  After  siRNA  transfection,  corneal
fibroblasts were lysed in a Triton lysis buffer (20 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1% v/v Triton
X-100).  Proteins  in  cell  lysates  were  quantified  by
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL)
with BSA as a standard. Equal amounts of proteins (20 µg/
lane) were resolved on 10% sodium dodecyl sulfate (SDS)-
polyacrylamide gels. The proteins were then transferred to
nitrocellulose membranes for probing with rabbit anti-LIMK1
antibody (1:500; Cell Signaling Technology Inc., Danvers,
MA) and horseradish peroxidase (HRP) conjugated goat anti-
rabbit IgG (1:5000; Jackson ImmunoReseach). As a protein
loading control, the membranes were also probed with anti-
glyceraldehyde  3-phosphate  dehydrogenase  (anti-GAPDH;
Trevigen,  Gaithersburg,  MD).  Signals  were  detected  by
chemiluminescence. The gel image captured with Gel Doc
2000 image analyzer (Bio-Rad, Hercules, CA) was analyzed
by densitometry using Image station 440 (Eastman Kodak
Company, Rochester, NY). Band intensities were determined
and the ratios of LIMK1 intensity to that of GAPDH were
calculated.
For  secreted  fibronectin,  72  h  following  transfection,
cells were incubated with serum-free media for 24 h. After
normalizing against the protein content in cell lysates, equal
aliquots of media samples were electrophoresed on 10% SDS
polyacrylamide  gels  under  reducing  conditions.
Immunoblotting  was  performed  using  rabbit  anti-human
fibronectin (1:5000) and HRP-goat anti-rabbit IgG (1:10000;
Jackson Immunoresearch).
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1952Wound closure assay for cell migration: Seventy-two hours
after transfection, corneal fibroblasts were scratched with a
sterile P20 pipette tip [24]. The migration of cells into the
wound was examined by phase-contrast microscopy 7 h after
wounding. Total area of the wound in each 10X field and the
area covered by the migrating cells within the wound were
measured using the Image Processing Tool Kit (Version 3.0;
Reindeer Graphics, Ashville, NC). At least 10 fields were
analyzed  and  the  mean  percentage  of  wound  area  was
calculated.  Student’s  t-test  was  used  for  the  statistical
analysis.
Mouse  model  of  subconjunctival  inflammation:  LIMK1
deficient  mice  were  described  elsewhere  [25].  The
experimental  protocol  was  approved  by  the  animal  care
committee at the University of Illinois at Chicago. Animal
care guidelines comparable to those published by the US
Public Health Service were followed. Mice underwent general
anesthesia  with  intraperitoneal  injections  of  ketamine  and
xylazine. The subconjunctival scarring model was generated
similar to that reported previously [26], with modifications
[8].  In  brief,  10  µl  of  phosphate  buffered  saline  (PBS)
containing  latex  beads  (1.053  µm  diameter,  300  µg/ml;
Polysciences, Warrington, PA) was injected to the temporal
subconjunctival space of mouse eyes. For experiments with
siRNA, the left eyes of mice were injected in a masked manner
with 10 µl of PBS/beads mixed with 0.1 µl of TransIT-TKO
and 100 nM of LIMK1 siRNA or scrambled siRNA. To serve
as controls, the left eyes of other mice were either untreated,
or  injected  with  PBS/latex  beads  or  with  TransIT-TKO
reagent alone. All the right eyes were untouched. Mice were
sacrificed by cervical dislocation 2 days after injection. At
least 5mice were used for each experiment.
The enucleated eyes were fixed with 10% PBS-buffered
formalin and 5 µm thick paraffin sections were prepared. The
sections were stained with hematoxylin and eosin to assess the
inflammatory reaction [26]. The number of round and large
inflammatory cells (as opposed to the long and thin resident
fibroblasts)  in  subconjunctival  areas  of  the  sections  was
counted.  The  value  was  normalized  to  number  of
inflammatory  cells  per  10,000  µm2  area  underneath  the
conjunctival  epithelium.  Tissue  sections  were  also
deparaffinized and stained with anti-CD45 antibody (1:200;
Santa  Cruz  Biotechnology,  Santa  Cruz,  CA)  and  FITC-
labeled goat anti-rabbit IgG (Jackson Immunoresearch) to
detect leukocytes. The number of anti-CD45-positive cells in
subconjunctival areas was determined as above.
RESULTS
LIMK1 siRNA inhibits fibronectin assembly and fibronectin
secretion: Endogenous LIMK1 was downregulated in human
corneal fibroblasts using a LIMK1-specific siRNA at both 48
and 72 h post-transfection time points. This siRNA was used
previously, proven to be effective in the 50–100 nM range in
silencing LIMK1 in human umbilical vein endothelial cells
[1]. The siRNA knockdown of the endogenous LIMK1 in
human corneal fibroblasts resulted in ~75% downregulation
with 50 nM, and ~80% downregulation with 100 nM siRNA
(Figure 1A).
Immunofluorescence microscopy was used to visualize
fibronectin deposition. Untreated human corneal fibroblasts
(Figure  1B)  and  those  transfected  with  scrambled  siRNA
(Figure 1C) exhibited abundant fibronectin deposition and a
substantial fibrillar network over cells (Figure 1B,C). The
fibronectin  deposition  was  significantly  diminished  in
cultures 48 (data not shown) and 72 h (Figure 1D,E) after
transfection with both 50 nM and 100 nM LIMK1 siRNA. Cell
density  was  similar  in  all  samples,  suggesting  that  the
decreased  fibronectin  assembly  was  not  related  to  the
reduction in cell numbers.
To determine whether the effect of LIMK1 siRNA on
fibronectin fibrillogenesis was due to a decreased fibronectin
secretion, we analyzed the amount of secreted fibronectin by
western  blotting  (Figure  1F).  Seventy-two  hours  after
transfection with LIMK1 siRNA, corneal fibroblasts, were
incubated in serum-free medium for 24 h. The fibronectin in
the media was detected as a 220 kDa protein band. Consistent
with the immunofluorescence data, treatment with 50 nM or
100  nM  LIMK1  siRNA  resulted  in  decreased  fibronectin
secretion into the culture; the reduction, up to 80%, was dose-
dependent.
LIMK1  siRNA  impairs  corneal  fibroblast  migration  and
reduces actin polymerization and focal adhesion formation:
A  scratch  wound  closure  assay  was  used  to  test  whether
downregulation of LIMK1 would affect corneal fibroblasts
motility. The data showed that corneal fibroblasts migrated
into the wounded area (Figure 2A,B). Within 7 h, untreated
(Figure  2A)  and  scrambled  siRNA  (100  nM)-transfected
(Figure 2B) cells filled approximately 83% of the wound area
(Figure  2E).  Meanwhile,  migration  was  significantly
decreased  in  LIMK1  siRNA  treated  cells.  The  percent  of
wound area covered was approximately 45% in the case of 50
nM (Figure 2C,E) and 28% in the case of 100 nM (Figure
2D,E) LIMK1 siRNA.
As actin cytoskeleton dynamics and cell adhesion to the
ECM  are  crucially  involved  in  cell  migration  [27],  we
investigated  whether  actin  dynamics  and  focal  adhesion
formation were affected upon downregulation of LIMK1. We
observed that cells treated with transfection reagent TransIt-
TKO alone as well as those transfected with scrambled siRNA
all  displayed  prominent  actin  stress  fibers.  Treatment  of
LIMK1 siRNA by contrast resulted in a substantial reduction
of  actin  stress  fibers  (Figure  3).  Staining  for  paxillin,  a
component  of  focal  adhesions,  was  also  decreased  by
LIMK1 siRNA in cultured corneal fibroblasts (Figure 3).
Downregulation  of  LIMK1  via  genetic  deletion  or  siRNA
reduces ocular inflammation in a mouse model: To generate
a mouse model of inflammation and fibrosis, PBS and latex
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1953beads were injected into the subconjunctival space of mice
[8]. This model is a modification of the previously described
one [26], in which PBS only was used for injections. In our
PBS/beads  model,  the  inflammation  response  was
significantly augmented as compared to PBS only [8]. The
augmentation of inflammatory response was detected by the
increased number of inflammatory cells per area underneath
the conjunctival epithelium [8].
Numerous  round  and  large  inflammatory  cells  were
observed  as  anticipated  underneath  the  conjunctival
epithelium  in  limk1+/+  2  days  after  PBS/beads  injection
(Figure  4A,B).  Quantitative  analyses  indicated  that  the
number of inflammatory cells was markedly lower in limk
1−/− mice (Figure 4A,B).
To  test  whether  direct  application  of  LIMK1-targeted
siRNA in the eyes would have the same anti-inflammatory
effects, we injected anti-mouse LIMK1 or negative control
siRNA  together  with  PBS/beads  into  the  subconjunctival
space in a masked manner. The robust inflammatory response
in the mice injected with scrambled siRNA was similar to that
with PBS/beads only (Figure 4B,C). By contrast, mice treated
with LIMK1-targeted siRNA exhibited reduced inflammatory
response as compared to the mice injected with scrambled
siRNA (Figure 4C).
To analyze the nature of inflammatory cells observed
upon injection with PBS/beads, tissue sections from limk1+/+
and limk1−/− mice were stained with an antibody for CD45, a
leukocyte marker. Consistent with that presented in Figure
4B, the data showed that the number of leukocytes upon the
injection  of  PBS/beads  in  limk1−/−  mice  was  significantly
fewer than in the limk1+/+ genotype (Figure 4D,E).
DISCUSSION
The present study demonstrates that siRNA specific to human
LIMK1  downregulated  the  protein  expression  in  cultured
Figure 1. LIMK1 siRNA downregulates LIMK1 protein and suppresses fibronectin deposition in human corneal fibroblasts. A: western blot
analysis. Corneal fibroblasts were transfected as indicated for 72 h. Cells were lysed and protein levels were analyzed using LIMK1 and
GAPGH antibodies. B-E: Immunofluorescence microscopy using fibronectin antibody and DAPI staining in fibroblast cultures (B) untreated;
(C) treated with 100 nM scrambled control siRNA; (D) treated with 50 nM of LIMK1-targeted siRNA; or (E) treated with 100 nM of
LIMK1-targeted siRNA. F: Quantitative analysis of fibronectin secreted to the culture media by western blotting. Samples were untreated or
treated with control or LIMK1-targeted siRNA as indicated. Experiments were performed 3 times yielding similar results. Error bars represent
standard deviation. The asterisk indicates a p<0.025 (n=3) compared to scrambled siRNA.
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1954human  corneal  fibroblasts.  LIMK1-targeted  siRNA
application  decreased  the  fibronectin  deposition,  reduced
actin  polymerization  and  focal  adhesion  formation,  and
retarded  migration  of  the  cells.  Corneal  fibroblasts
constitutively express TGF-β, which is known to induce the
expression  of  matrix  molecules  such  as  fibronectin  and
collagen type I [28,29] and facilitate migration of corneal
fibroblasts  [29,30].  Both  of  these  are  crucial  steps  in  the
wound repair process [31]. Therefore, our data suggests that
LIMK1 might be involved in the wound repair, regulating both
transcriptional and migratory signaling pathways associated
with TGF-β.
Several  reports  demonstrated  the  interaction  between
LIMK and TGF-β superfamilies. A direct association between
LIMK1 and BMPR-II, a member of the TGF-β superfamily,
was documented to result in influences on actin cytoskeleton
dynamics [14,15]. Also, LIMK2, a member of the LIMK
family, can be indirectly activated by TGF-β type I receptor
through Rho and ROCK1 [16] to regulate actin assembly. In
this  report,  we  demonstrated  another  possible  cross-talk
between  LIMK  and  TGF-β,  notably  in  the  wound  repair
signaling.
We  observed  that  LIMK1  may  be  involved  in  the
regulation  of  both  migratory  and  transcriptional  signaling
pathways  mediated  by  TGF-β.  The  influence  of  LIMK1
downregulation on TGF-β-dependent cell migration may be
explained by the impairment of effective actin cytoskeleton
dynamics since LIMK1 downregulation resulted in reduced
actin  polymerization,  fibronectin  deposition,  and  focal
adhesion formation (Figure 3 and [1]). The links between
LIMK1  and  transcriptional  pathways  regulated  by  TGF-β
however are less clear. The reduced production of fibronectin
could be a result of diminished actin polymerization as it is
known  that  ECM  signaling  is  largely  connected  to  actin
cytoskeleton dynamics [32]. Alternatively, LIMK1 could also
act directly on transcriptional pathways given the facts that
LIMK1 possesses two LIM domains [33], which may bind
DNA; and that there have been reports describing LIMK1
nuclear localization [34] and its direct effects on the protein
expression [35].
We  demonstrate  that  downregulation  of  LIMK1  via
genetic  deletion  or  direct  application  of  mouse  LIMK1-
targeted siRNA in the eyes of a mouse model significantly
decreased  ocular  inflammatory  response.  As  previously
described [4], we injected PBS mixed with latex beads into
Figure 2. LIMK1-targeted siRNA blocks corneal fibroblast migration. A-D: Phase contrast micrographs demonstrating migration of (A)
untreated cells; (B) cells treated with 100 nM scrambled control siRNA; (C) cells treated with 50 nM LIMK1-targeted siRNA; (D) cells treated
with 100 nM LIMK1-tareted siRNA into the scratched wound area (marked by dotted white lines). E: Bar graph showing mean percentage of
scratch-wounded area covered by migrating corneal fibroblasts in each specimen (n=10); error bars represent standard error of the mean.
Asterisks denote values significantly different from those of samples treated with scrambled control siRNA (p<0.0001 [n=10] compared to
scrambled siRNA). Experiments were repeated 3 times, yielding similar results.
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1955mouse eyes to induce inflammation [8]. We observed in 2 days
that  both  limk1−/−  mice  and  wild  type  mice  treated  with
LIMK1-targeted  siRNA  had  much  lessened  inflammatory
response,  as  evidenced  by  decreased  infiltration  of
inflammatory cells such as leukocytes. The fibrosis response
presumably was also reduced as it is related to the reduced
inflammation  (unpublished  data),  impeded  fibroblast
migration, and declined matrix deposition.
Figure 3. Downregulation of LIMK1 decreases actin polymerization and focal adhesion formation. Corneal fibroblasts transfected with
TransIT-TKO transfection reagent, a 100 nM scrambled or LIMK1 siRNA for 72 h were fixed and permeablized. The cells were stained for
actin (green color, using Alexa 488 phalloidin) and paxillin (red color, using anti-paxillin and Cy3-goat anti-mouse IgG) where indicated. The
nuclei were stained with DAPI (blue color). Note the reduction of actin stress fibers and paxillin-positive focal adhesions in LIMK1 siRNA-
transfected cells. Bar, 20 μm.
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1956The siRNA injected into mouse eyes most likely targeted
fibroblasts  in  the  subconjunctival  region.  The  precise
mechanism of how siRNA was entering the cells is not known.
The siRNA treatment reduced the inflammation, possibly in
association with the attenuation of chemotaxis. As is shown
in Figure 2 and Figure 3, LIMK1 siRNA treatment retarded
the migration and altered actin dynamics of corneal fibroblasts
in culture. Downregulation of LIMK1 in leukocytes was also
observed  to  decrease  leukocyte  chemotaxis  in  Transwell
Figure 4. Suppression of inflammatory
response by downregulation of LIMK1
in  a  mouse  model  of  ocular
inflammation. A: Tissue sections from
the mouse eyes of limk1+/+  and limk1−/−
  genotypes  treated    with  PBS/beads
where indicated. B: Bar graph showing
the number of inflammatory cells per
10,000 μm2 of subconjunctival area in
PBS/beads-injected eyes of limk1+/+ and
limk1−/− mice. The asterisk indicates a
p=0. 028 (n=4) compared with limk1+/+
(n=5)  specimens.  C:  Bar  graph
showing  the  number  of  inflammatory
cells per 10,000 µm2 of subconjunctival
area  in  eyes  of  mice  treated  with
scrambled  siRNA  or  LIMK1-targeted
siRNA  where  indicated.  The  asterisk
indicates  a  p=0.  024  (n=8)  compared
with  scrambled  siRNA  controls.  D:
Immunofluorescence  analysis  of
leukocyte  infiltration  in  PBS/beads-
injected  limk1+/+  and  limk1−/−  mouse
eyes. Sections were stained with anti-
CD45 antibody, and the cellularity was
assessed by the co-staining with DAPI.
White  arrowheads  indicate  CD45-
positive cells. E: Bar graph showing the
number of leukocytes per 10,000 μm2 of
subconjunctival area in the PBS/beads-
treated  eyes  of  limk1+/+  (n=5)  and
limk1−/−  (n=4)  mice.  The  asterisk
indicates a p=0.027. Experiments were
performed 3 times.
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1957assay, presumably via impairment of actin polymerization
(unpublished data).
It is noteworthy that while adenovirus and other vectors
may be employed for long-term inhibition of inflammation,
transient  knockdown  by  synthetic  siRNA  allows  a  better
dosage control to minimize potential side effects. In our model
a one-time administration of siRNA at a very early phase was
sufficient to reduce the pathway of inflammation.
Ocular fibrotic wound response is a major cause of vision
handicap  and  blindness,  especially  following  surgical
treatment  for  glaucoma  [17,18].  Excessive  post-operative
scarring often leads to failure of filtration surgery. While the
use of antimetabolites such as mitomycin C and 5-fluorourcil
as  conjunctival  anti-fibrosis  or  anti-scarring  treatments
benefits  some  patients,  these  agents  are  associated  with
potentially  blinding  complications  including  hypotony,
maculopathy,  and  infection  [19-22].  Therefore
downregulation of LIMK1 might be an effective strategy in
suppression  and  prevention  of  ocular  inflammation  and
fibrosis.
To summarize, we report that LIMK1-targeted siRNA
application in vitro resulted in decreased fibrosis, reduced
actin polymerization, and retarded migration of fibroblasts,
disclosing a possibility that LIMK1 may mediate TGF-β-
dependent  signaling  during  ocular  inflammation.  Also,
downregulation  of  LIMK1  via  genetic  deletion  or  direct
application of LIMK1-targeted siRNA in the eyes of a mouse
model  markedly  decreased  ocular  inflammatory  response.
The in vitro and in vivo results underscore the potential of a
novel therapy for preventing the inflammatory response and
fibrosis or scarring in ocular diseases and after glaucoma
filtration surgery. This approach may also have applications
for other surface tissues, including the skin.
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